Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score
Joanna Rupa‐Matysek(Poznan University of Medical Sciences), Mieczysław Komarnicki(Poznan University of Medical Sciences), Lidia Gil(Poznan University of Medical Sciences), Maciej Kaźmierczak(Silesian University of Technology), Marta Barańska(Poznan University of Medical Sciences)
Cited by 49
Related Papers
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
|Journal of Clinical Oncology|2022|93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR
|International Journal of Oncology|2017|80